Search research articles
Contact Us
Filters
Showing results (451-460 of 692) with videos related to
Page
of 70
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging
|
April 28, 2023
Development of a simple standardized scoring system for assessing large vessel vasculitis by 18F-FDG PET-CT and differentiation from atherosclerosis
Y A A Bacour, M P van Kanten, F Smit, et al.
Revista Espanola De Medicina Nuclear E Imagen Molecular
|
May 29, 2019
Freehand-SPECT with <sup>99m</sup>Tc-HDP as tool to guide percutaneous biopsy of skeletal lesions detected on bone scintigraphy
D D D Rietbergen, P Meershoek, M N van Oosterom, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 28, 2004
Combination therapy with gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin in patients with advanced solid tumors
G Giaccone, J L González-Larriba, A T van Oosterom, et al.
Cellular Oncology : the Official Journal of the International Society for Cellular Oncology
|
September 18, 2009
A panel of high resolution melting (HRM) technology-based assays with direct sequencing possibility for effective mutation screening of EGFR and K-ras genes
D A M Heideman, F B Thunnissen, M Doeleman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 25, 2009
Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer
Egbert F Smit, Sjaak A Burgers, Bonne Biesma, et al.
Lung Cancer (Amsterdam, Netherlands)
|
January 8, 2004
Critical factors for patient management
V Ninane, C Le Pechoux, W Curran, et al.
Lung Cancer (Amsterdam, Netherlands)
|
January 30, 2013
Concurrent chemoradiotherapy for large-volume locally-advanced non-small cell lung cancer
Terry G Wiersma, Max Dahele, Wilko F A R Verbakel, et al.
Cancer Chemotherapy and Pharmacology
|
May 4, 2018
Exposure-response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancer
Egbert F Smit, Edward B Garon, Martin Reck, et al.
Molecular Oncology
|
August 13, 2014
Whole genome RNAi screens reveal a critical role of REV3 in coping with replication stress
Ilya N Kotov, Ellen Siebring-van Olst, Philip A Knobel, et al.
Cancer Discovery
|
July 31, 2014
Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations
Yelena Y Janjigian, Egbert F Smit, Harry J M Groen, et al.
Page
of 70
Search research articles
Search
Showing results (451-460 of 692) with videos related to
Sort By:
Page
of 70
European Journal of Nuclear Medicine and Molecular Imaging
|
April 28, 2023
Development of a simple standardized scoring system for assessing large vessel vasculitis by 18F-FDG PET-CT and differentiation from atherosclerosis
Y A A Bacour, M P van Kanten, F Smit, et al.
Revista Espanola De Medicina Nuclear E Imagen Molecular
|
May 29, 2019
Freehand-SPECT with <sup>99m</sup>Tc-HDP as tool to guide percutaneous biopsy of skeletal lesions detected on bone scintigraphy
D D D Rietbergen, P Meershoek, M N van Oosterom, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 28, 2004
Combination therapy with gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin in patients with advanced solid tumors
G Giaccone, J L González-Larriba, A T van Oosterom, et al.
Cellular Oncology : the Official Journal of the International Society for Cellular Oncology
|
September 18, 2009
A panel of high resolution melting (HRM) technology-based assays with direct sequencing possibility for effective mutation screening of EGFR and K-ras genes
D A M Heideman, F B Thunnissen, M Doeleman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 25, 2009
Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer
Egbert F Smit, Sjaak A Burgers, Bonne Biesma, et al.
Lung Cancer (Amsterdam, Netherlands)
|
January 8, 2004
Critical factors for patient management
V Ninane, C Le Pechoux, W Curran, et al.
Lung Cancer (Amsterdam, Netherlands)
|
January 30, 2013
Concurrent chemoradiotherapy for large-volume locally-advanced non-small cell lung cancer
Terry G Wiersma, Max Dahele, Wilko F A R Verbakel, et al.
Cancer Chemotherapy and Pharmacology
|
May 4, 2018
Exposure-response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancer
Egbert F Smit, Edward B Garon, Martin Reck, et al.
Molecular Oncology
|
August 13, 2014
Whole genome RNAi screens reveal a critical role of REV3 in coping with replication stress
Ilya N Kotov, Ellen Siebring-van Olst, Philip A Knobel, et al.
Cancer Discovery
|
July 31, 2014
Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations
Yelena Y Janjigian, Egbert F Smit, Harry J M Groen, et al.
Page
of 70